Technical Analysis for AZNCF - Astrazeneca Plc Ord

Grade Last Price % Change Price Change
A 131.08 3.16% 4.0200
AZNCF closed up 3.16 percent on Monday, May 23, 2022, on 67 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Resistance Bearish 3.16%
MACD Bullish Signal Line Cross Bullish 3.16%
NR7 Range Contraction 3.16%
Gapped Down Weakness 4.11%
Fell Below 20 DMA Bearish 4.45%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 20 DMA about 9 hours ago
Rose Above Upper Bollinger Band about 9 hours ago
Rose Above 50 DMA about 9 hours ago
Rose Above Previous Day's High about 9 hours ago
Up 5% about 9 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Astrazeneca Plc Ord Description

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Chemistry Cancer Partnership Organic Compounds Chemical Compounds Small Cell Bicycle Cardiovascular Disease Neuroscience Primary Care Metabolic Diseases Lung Cancer Metabolic Disease Rimi Vascular Diseases Cardiovascular Diseases Nexi Qt Small Cell Lung Cancer Bristol Myers Squibb Chloroarenes Dax Byd Respiratory Diseases Astrazeneca Respiratory Disease Xr Idex Zest Combination Therapy Gastrointestinal Diseases Seroquel Xr Tecan

Is AZNCF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 143.9
52 Week Low 105.26
Average Volume 2,456
200-Day Moving Average 120.6336
50-Day Moving Average 130.4368
20-Day Moving Average 127.1655
10-Day Moving Average 125.8320
Average True Range 4.6217
RSI 54.75
ADX 9.05
+DI 32.2332
-DI 24.5472
Chandelier Exit (Long, 3 ATRs) 121.3649
Chandelier Exit (Short, 3 ATRs) 133.8651
Upper Bollinger Bands 133.4635
Lower Bollinger Band 120.8675
Percent B (%b) 0.81
BandWidth 9.9052
MACD Line -0.9454
MACD Signal Line -1.4087
MACD Histogram 0.4633
Fundamentals Value
Market Cap 172.02 Billion
Num Shares 1.31 Billion
EPS 1.90
Price-to-Earnings (P/E) Ratio 68.99
Price-to-Sales 5.37
Price-to-Book 11.38
PEG Ratio 1.23
Dividend 2.71
Dividend Yield 2.07%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 135.2650
Resistance 3 (R3) 135.7300 134.8000 134.5675
Resistance 2 (R2) 134.8000 133.7342 134.5675 134.3348
Resistance 1 (R1) 132.9400 133.0758 132.4750 132.4750 134.1024
Pivot Point 132.0100 132.0100 131.7775 131.7775 132.0100
Support 1 (S1) 130.1500 130.9442 129.6850 129.6850 128.0576
Support 2 (S2) 129.2200 130.2858 128.9875 127.8252
Support 3 (S3) 127.3600 129.2200 127.5925
Support 4 (S4) 126.8950